Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity.

Journal of controlled release : official journal of the Controlled Release Society - 10 Jan 2021

Zhao Pengfei, Zhang Jiaxin, Wu Aihua, Zhang Meng, Zhao Yuge, Tang Yisi, Wang Bing, Chen Tianxiang, Li Feng, Zhao Qiang, Huang Yongzhuo

Abstract excerpt

The third-generation of EGFR-TKI osimertinib has been approved as a first-line therapy in NSCLC, representing the most successful advance in molecularly targeted therapy. However, the rapid development of osimertinib resistance renders the unsustainable treatment benefit. Plus, brain metastasis (BMs) is a major mortality cause for NSCLC; there is no drug specifically approved for the osimertinib-resistant BMs of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomimetics

Share to Brain Neoplasms

Share to Drug Resistance, Neoplasm

Share to Immunity, Innate

Share to Macrophages

Share to Tumor Microenvironment

Source

Identifiers

PMID: 33129919
DOI: 10.1016/j.jconrel.2020.10.052

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity.PMID 33129919Read ↗

Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages.Semantic proximity Read ↗

BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFRT790M mutation.Semantic proximity Read ↗

Reprogramming Tumor-Associated Macrophages To Reverse EGFRT790M Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat.Semantic proximity Read ↗

Systemic delivery of a CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapySemantic proximity Read ↗

Self-Assembled Tetrahedral Framework Nucleic Acid Mediated Tumor-Associated Macrophages Reprogramming and Enhancing Cancer ImmunotherapySemantic proximity Read ↗

Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer.Semantic proximity Read ↗

A homologous-targeting "nanoconverter" with variable size for deep tumor penetration and immunotherapy.Semantic proximity Read ↗

Nanocatalytic Innate Immunity Activation by Mitochondrial DNA Oxidative Damage for Tumor‐Specific TherapySemantic proximity Read ↗

Nanomedicine Strategies for Management of Drug Resistance in Lung CancerSemantic proximity Read ↗

Immunotherapy: an emerging modality to checkmate brain metastasisSemantic proximity Read ↗

Effective Degradation of Wild-Type and Mutant EGFR Using Self-Assembling Peptide-Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy.Semantic proximity Read ↗

Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.